Maverick Therapeutics, Takeda deal

Maverick and Takeda partnered to develop the biotech’s T cell engagement platform to improve T cell redirection therapies. Takeda provided $125 million in funding split across an upfront option payment, R&D payments and the pharma’s investment within Maverick’s concurrent $23 million series B venture round. Takeda gained an exclusive option to acquire Maverick after five years for an undisclosed price. The partners declined to disclose the funding breakdown and option terms...